The emergence of drug-resistant TB remains a global health threat, with only one-third of individuals estimated to have multi-drug (MDR) or rifampicin-resistant (RR) TB diagnosed and treated annually. While culture-based methods remain the standard for drug susceptibility testing (DST), they are not widely available and have long turnaround times for results, resulting in delays in diagnosis, treatment failure, and ongoing transmission of resistant strains. In 2023, the WHO recommended using targeted next-generation sequencing (tNGS) for detecting and managing drug-resistant TB. ASLM organized a four-part series to help countries share best practices for implementing tNGS. In the third session of the series, Dr Debrah Vambe discussed how Eswatini is pioneering the use of next generation sequencing (NGS) technology as an essential tool in the diagnosis and management of drug-resistant TB. She provided practical insights into the implementation roadmap for tNGS, including integration into diagnostic algorithms. Please follow the links here to view the recorded ECHO session and download the presentation slides.